Alcon’s global headquarters to move ahead of Novartis spinoff
Alcon, a global leader in eye care and a division of Novartis, on Tuesday announced plans to locate its future global headquarters in the Canton of Geneva, Switzerland, following completion of its proposed spinoff from Novartis. Alcon corporate and EMEA employees will begin moving to the new Geneva location in 2019.
Earlier this year, Novartis announced its intention to spinoff Alcon into a separately-traded standalone company.
Alcon’s new global headquarters in Geneva will be the primary location for Alcon’s senior corporate leadership and other corporate and commercial functions. It will be co-located with Alcon’s Europe, Middle East, and Africa (EMEA) regional office, which is already based in the city.
“We are delighted to announce Geneva as the location of Alcon’s new global headquarters following the proposed spinoff from Novartis,” Alcon’s chief executive officer, David Endicott said. “For more than 40 years, Alcon has had a significant presence in Switzerland, which is known for its progressive business climate and innovation-friendly policies. Being headquartered in Geneva will help further increase Alcon’s global scale and reach to better serve our customers.”
The new listed holding company for the Alcon group after the proposed spinoff will be incorporated in the Canton of Fribourg, where Alcon already has significant operations, which will complement other key sites in Rotkreuz and Schaffhausen.
Alcon could employ up to 700 in Switzerland post-spin-off. Alcon’s current global divisional headquarters in Fort Worth, Texas, will remain a major operational, commercial, and innovation hub for the proposed standalone company, according to the company.
Liberty Software’s Amplicare integration helps pharmacies improve workflow
Pharmacies using Liberty Software are able to proactively improve patient care through Liberty’s pharmacy software integration with Amplicare, a leading decision automation platform that uses patient data and intelligently identifies opportunities for healthcare providers.
The proactive alerts integrated with Liberty’s platform offer a greater range of workflow automation for pharmacists to improve productivity and patient care.
“With the tighter integration of Amplicare’s platform to Liberty Software’s platform, our pharmacies are the first in the marketplace to receive proactive patient opportunities in their daily workflow within the pharmacy software and fully quantifiable ROI through the pharmacy POS integration,” Liberty Software’s executive vice president Jeremy Manchester said. “Liberty Software is always looking for ways to improve patient care, and this seamless, integrated solution with Amplicare is a strategic fit that will prove invaluable for our pharmacies.”
The Amplicare platform features the following:
- Amplicare Connect improves patient satisfaction by helping them with adherence and staying on top of their refills with automated phone calls in the voice of their pharmacist;
- Amplicare Restore recognizes patients who could benefit from taking over-the-counter supplements based on their active prescriptions that deplete key nutrients;
- Amplicare Impact helps pharmacies identify opportunities to interact with patients who are impacting their performance metrics;
- iMedicare enables pharmacies to compare Medicare plans in seconds, improves patient retention, drives new business and improves patient care; and
- Amplicare Assist automatically highlights opportunities generated from any of the other Amplicare tools, tying everything together in the pharmacy daily workflow without the need to visit another dashboard to retrieve opportunities.
“Pharmacies have more dashboards today than ever before, yet less time to perform the key activities that need their greatest attention,” Amplicare CEO Matt Johnson said. “By deeply integrating with Liberty Software, we empower pharmacies to execute on the most valuable interventions for their patients at the right time and place in their daily workflow.”
Grifols’ Gamastan formulation gets FDA approval for HAV, measles
Grifols, a leading global producer of plasma-derived medicines, has received the green light from the Food and Drug Administration for a new formulation of its Gamastan immune globulin (human) for hepatitis A virus (HAV) and measles postexposure prophylaxis.
Gamastan, which is available in 10 mL and 2 mL vials, is manufactured using a sophisticated caprylate chromatography process, according to the highest quality and safety standards, and includes labeling for capacity to remove prions, the company said.
Gamastan is the only immune globulin product on the U.S. market approved for immediate protection against HAV and measles. The FDA approval is an important research and development milestone for Grifols as a global leader in postexposure prophylaxis — the treatment of a person after exposure to a virus — and immune globulin products for patients, according to the company.
“Vaccination, while a valuable option for hepatitis A and measles postexposure prophylaxis, may take several weeks to take effect as your immune system works to build the antibodies it needs to fight these viruses,” MidState Medical Center infectious disease specialist Stephen Scholand said. “Immune globulins such as Gamastan have been a valuable treatment option for many decades because they offer immediate and rapid protection with antibodies that fight infection.”
The Centers for Disease Control and Prevention states that for persons age 40 years old and older, an immune globulin is preferred for HAV postexposure prophylaxis. The CDC also recommends that immune globulin should be used for children aged less than 12 months, immunocompromised persons, persons with chronic liver disease and persons who are allergic to the vaccine or a vaccine component. When administered within two weeks after exposure to HAV, immune globulin is 80% to 90% effective in preventing hepatitis A infection, according to the CDC.
Gamastan also is approved for rubella and varicella postexposure prophylaxis.
“As a company driven by innovation, we strive to provide the highest-quality products possible to our patients” Grifols North America sales and commercial operations president Bill Zabel said in a statement. “This advancement in the Gamastan formulation marks an important milestone in Grifols’ ongoing R&D efforts, and we are confident that it will continue to be an important treatment option for healthcare providers.”